New drug cocktail aims to shrink lymphoma without chemo
NCT ID NCT03789240
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over several cycles. The main goal is to see how many achieve a complete response on a PET scan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Copanlisib and rituximab
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for follicular lymphoma, potentially improving response rates without chemotherapy.
- What could go wrong
- This is a small, early-phase trial (33 people) with no control group. Results may not generalize, and side effects could lead to stopping treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?